Investors in Hong Kong are catching biotech fever
At least seven senior bankers and analysts of the Tipti Securities firm are going to join the biotechnology companies in the city from December to increase demand for industry progress after changing rules in Hong Kong's stock exchange, so that the path of biotechnology primary public reserve gradually becomes a reality. .
Richard Yay, a healthcare analyst at the Goldman Sachs Group, said yesterday that he would join the chief financial officer of the City of Stonestones Pharmaceuticals. Similar inspections have been found in recent months including Lazard Limited, Bank of America Corp., Deutsche Bank AG, CityGroup Input and Jefferyn Group LLC.
Like the Internet Boom and more recent Cryptoconjancer Gold Rash in the 1990s, Hong Kong's financial stock options are suddenly going to suddenly appear in hopes of hitting the jackpot.
At least 16 biotech firms are following the IPO in British colonies, they want to increase the company's filing and the amount of $ 3 billion according to the people familiar with the matter.
"During the dot-less era, everyone wanted to go to the Internet startup company because it was a new thing, it was exciting, if the company made it in the IPO it is likely to cost a lot," said Hogan Lovells, a capital market lawyer in Hong Kong, Stephen Peepels said. "I think it's equivalent to Hong Kong's healthcare industry."
Small and large biotech companies worldwide are attracted, but the Hong Kong fundraising program is being transferred to Overdrave after April's decision to allow the IPO of an unexpected biotech business in exchange for the city - the largest branch in the listing market within two decades.
"We can see very good interest from quality issuers and we expect a balanced pipeline for the next few years," said David Lau, Hong Kong Investment Bank chief JP Morgan Chase and Co. ".
JHL Biotech Inc, which in May was hired by contract manufacturers Alice Chu and Lee Henley, to sell the city's shares.
Alternative Alternative Cancer Dealers want to raise US $ 350 million in next year's IPO, said one who asked to not sign because the details are personal.
"I'm going to a sector where I see huge potential," Chu said in a phone interview. "Biotech is an art that explodes, yet in China, there are all kinds of tailwinds."
Of course, early crocodile risks of biotech and anyone who predicts that the upcoming Hong Kong IPO will achieve long-term success of the new crop.
But for those who join the winners, the money can be much more, the director of managing the services of financial services in Robert Walter's PLC in Hong Kong.
"If you get enough time at a sufficient level, you are going to reward it with a certain amount of equity at the beginning," he said. "Going up can be countless."